This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Goldhaber, S. Z. Search for Related Content PubMed PubMed Citation Articles by Goldhaber, S. Z. Related Collections Arterial thrombosis Coagulation Heparin Coumarins Thrombosis risk factors CV surgery: valvular disease Embolic stroke

(Circulation. 2006;113:470-472.)
© 2006 American Heart Association, Inc.

Editorial

"Bridging" and Mechanical Heart Valves

Perils, Promises, and Predictions

Samuel Z. Goldhaber, MD

From the Cardiovascular Division, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA

Correspondence to Samuel Z. Goldhaber, MD, Cardiovascular Division, Brigham and Women’s Hospital, 75 Francis St, Boston, MA 02115. E-mail sgoldhaber@partners.org

Key Words: Editorials • anticoagulants • stroke • thrombosis • valves

An extract of the first 250 words of the full text is provided, because this article has no abstract.

Mechanical heart valves require anticoagulation to prevent valve-associated thrombosis and thromboembolic stroke. Oral vitamin K antagonists such as warfarin are prescribed universally; however, oral agents do not act immediately and usually require at least 5 days to achieve a therapeutic effect.

Article p 564

Measurement of the prothrombin time, which is standardized by reporting the result as the international normalized ratio (INR), assesses the anticoagulant effect of warfarin. For most mechanical heart valves, the target INR ranges between 2.0 and 3.5. In the postoperative cardiac surgical setting, patients are usually started on low doses of warfarin because they tend to have impaired hepatic metabolism and suboptimal nutritional status. Even with low initial doses of warfarin, mechanical heart valve replacement patients are susceptible to excessively high INRs.¹ This known exaggerated initial response to warfarin after heart valve replacement can lead to the habitual prescription of such low warfarin doses that warfarin as monotherapy may not achieve a stable and therapeutic INR for weeks after its initiation.

To minimize the delay in achieving therapeutic anticoagulation, a "bridging" anticoagulant is prescribed. The "bridge" is administered parenterally, thereby providing an immediate anticoagulant effect. Traditionally, the "bridging" agent has been unfractionated heparin (UFH). More recently, physicians tend to select low-molecular-weight heparin (LMWH), even though few studies exist to validate the efficacy and safety of either LMWH or UFH in this setting.

The rationale for shunning UFH has been to avoid the known perils and inconveniences of its use as a continuous peripheral intravenous infusion. UFH . . . [Full Text of this Article]

This article has been cited by other articles:

				P. Meurin and J. Y. Tabet Can we use a low molecular weight heparin after mechanical prosthetic heart valve surgery? Heart, February 1, 2008; 94(2): 131 - 132. [Full Text] [PDF]